Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for nicotine craving and symptoms in male smokers with schizophrenia
IRCT20250517065767N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence and schizophrenia comparing Oxytocin with Placebo (2 arms). Primary endpoints: Nicotine craving, Clinical symptoms of schizophrenia and 1 more. Started Aug 2025; status: completed.
02
Drugs
oxytocin
03
Conditions
nicotine dependenceschizophrenia
Beyond the preview
Go deeper on IRCT20250517065767N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250517065767N1.